Newer antidepressants and other nonhormonal agents for the treatment of hot flashes.
The reluctance to use estrogen in breast cancer survivors with hot flashes has extended to its use in healthy women since the 2002 publication of the Women's Health Initiative study. This article reviews the clinical development of nonhormonal agents as alternatives to hormonal therapy for the management of hot flashes.
Perez
Domingo G
DG
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Loprinzi
Charles L
CL
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000588:Amines / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D031885:Cimicifuga; D003000:Clonidine / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D004347:Drug Interactions; D005260:Female; D000077206:Gabapentin; D019584:Hot Flashes / Q000188:drug therapy*; D006801:Humans; D007529:Isoflavones / Q000627:therapeutic use; D008517:Phytotherapy; D014810:Vitamin E / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000316:Adrenergic alpha-Agonists; D000588:Amines; D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D000975:Antioxidants; D003509:Cyclohexanecarboxylic Acids; D007529:Isoflavones; D014810:Vitamin E; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D003000:Clonidine